Disappointed to see this drifting gently south, my guess is other opportunities for more rapid gratification. Can't see a policy shift on dose sales reporting, R&D show may be a catalyst otherwise the main game really isn't until next year. T/O offer also probably unlikely in absence of trial data confirmation. Keeping the faith, but I would not at all be surprised if this gets cheaper short term.
Ann: Statement by CEO on Sale of Shares, page-17
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)